CA1142175A - Fractionation of protein mixtures by salting out followed by dialysis treatment - Google Patents
Fractionation of protein mixtures by salting out followed by dialysis treatmentInfo
- Publication number
- CA1142175A CA1142175A CA000371840A CA371840A CA1142175A CA 1142175 A CA1142175 A CA 1142175A CA 000371840 A CA000371840 A CA 000371840A CA 371840 A CA371840 A CA 371840A CA 1142175 A CA1142175 A CA 1142175A
- Authority
- CA
- Canada
- Prior art keywords
- mixture
- turbidity
- process according
- proteins
- salting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 38
- 238000005185 salting out Methods 0.000 title claims abstract description 25
- 238000000502 dialysis Methods 0.000 title claims abstract description 24
- 238000005194 fractionation Methods 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 43
- 102000009027 Albumins Human genes 0.000 claims abstract description 23
- 108010088751 Albumins Proteins 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 6
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 6
- 229940072221 immunoglobulins Drugs 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 17
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 9
- 102000004506 Blood Proteins Human genes 0.000 claims description 8
- 108010017384 Blood Proteins Proteins 0.000 claims description 8
- 102000008946 Fibrinogen Human genes 0.000 claims description 7
- 108010049003 Fibrinogen Proteins 0.000 claims description 7
- 229940012952 fibrinogen Drugs 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000003058 plasma substitute Substances 0.000 claims 1
- 239000006228 supernatant Substances 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 239000011800 void material Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 19
- 238000002616 plasmapheresis Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010054218 Factor VIII Proteins 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000005686 Serum Globulins Human genes 0.000 description 2
- 108010045362 Serum Globulins Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 206010020740 Hyperproteinaemia Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/144—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by electrical means, e.g. electrodialysis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/06—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/42—Electrodialysis; Electro-osmosis ; Electro-ultrafiltration; Membrane capacitive deionization
- B01D61/44—Ion-selective electrodialysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/303—Extraction; Separation; Purification by precipitation by salting out
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S128/00—Surgery
- Y10S128/22—Blood coagulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Water Supply & Treatment (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/197,441 US4321192A (en) | 1980-01-10 | 1980-10-16 | Fractionation of protein mixtures by salt addition followed by dialysis treatment |
| US197,441 | 1980-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1142175A true CA1142175A (en) | 1983-03-01 |
Family
ID=22729448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000371840A Expired CA1142175A (en) | 1980-10-16 | 1981-02-26 | Fractionation of protein mixtures by salting out followed by dialysis treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4321192A (OSRAM) |
| JP (1) | JPS5772916A (OSRAM) |
| CA (1) | CA1142175A (OSRAM) |
| DE (1) | DE3112539A1 (OSRAM) |
| FR (1) | FR2492270A2 (OSRAM) |
| GB (1) | GB2085446B (OSRAM) |
| IT (1) | IT1142464B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087695A (en) * | 1988-07-29 | 1992-02-11 | Mcy Laboratories Canada, Inc. | Immunoglobulin extraction utilizing properties of colloidal solutions |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4426323A (en) | 1980-01-10 | 1984-01-17 | Ionics, Incorporated | Selected recovery of proteins from fermentation broths |
| US4435318A (en) | 1981-05-22 | 1984-03-06 | Ionics, Incorporated | Electrodialysis preparation of purified AHF concentrate |
| JPS58155865A (ja) * | 1982-03-12 | 1983-09-16 | 株式会社クラレ | 血漿処理用中空糸膜 |
| JPS6099266A (ja) * | 1983-11-07 | 1985-06-03 | テルモ株式会社 | 体液中の蛋白質除去法およびそれに使用する装置 |
| JPS6099265A (ja) * | 1983-11-07 | 1985-06-03 | テルモ株式会社 | 体液中の蛋白質除去装置 |
| SE8402861L (sv) * | 1984-05-28 | 1985-11-29 | Stefan Svenson | Rening av biologiskt material |
| US4663049A (en) * | 1984-07-05 | 1987-05-05 | University Of Utah | Process for therapeutic dissociation of immune complexes and removal of antigens |
| JPS6164259A (ja) * | 1984-09-07 | 1986-04-02 | テルモ株式会社 | 血漿蛋白質分画分離剤および装置 |
| US4678566A (en) * | 1984-07-20 | 1987-07-07 | Terumo Kabushiki Kaisha | Apparatus for separating proteins from blood plasma |
| JPH06104122B2 (ja) * | 1985-09-19 | 1994-12-21 | 東レ株式会社 | β▲下２▼−ミクログロブリン除去カラム |
| US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| EP0396402A3 (en) * | 1989-05-02 | 1991-06-19 | Alliance Pharmaceutical Corporation | Cell growth activators |
| US5217618A (en) * | 1991-08-26 | 1993-06-08 | Terumo Kabushiki Kaisha | Plasma purification treatment |
| US5804079A (en) * | 1991-12-23 | 1998-09-08 | Baxter International Inc. | Systems and methods for reducing the number of leukocytes in cellular products like platelets harvested for therapeutic purposes |
| US5549834A (en) * | 1991-12-23 | 1996-08-27 | Baxter International Inc. | Systems and methods for reducing the number of leukocytes in cellular products like platelets harvested for therapeutic purposes |
| US5643193A (en) * | 1995-12-13 | 1997-07-01 | Haemonetics Corporation | Apparatus for collection washing and reinfusion of shed blood |
| US20060076295A1 (en) * | 2004-03-15 | 2006-04-13 | The Trustees Of Columbia University In The City Of New York | Systems and methods of blood-based therapies having a microfluidic membraneless exchange device |
| ATE510605T1 (de) * | 2003-03-14 | 2011-06-15 | Univ Columbia | Systeme und verfahren für auf blut basierende therapien mit einer membranlosen mikrofluid- austauschvorrichtung |
| US7959780B2 (en) | 2004-07-26 | 2011-06-14 | Emporia Capital Funding Llc | Textured ion exchange membranes |
| US7780833B2 (en) * | 2005-07-26 | 2010-08-24 | John Hawkins | Electrochemical ion exchange with textured membranes and cartridge |
| US7879332B2 (en) * | 2005-09-01 | 2011-02-01 | Plasma Technologies, Llc | Ultra-high yield intravenous immune globulin preparation |
| US20070049732A1 (en) * | 2005-09-01 | 2007-03-01 | Zurlo Eugene J | Ultra-high yield intravenous immune globulin preparation |
| US8293242B2 (en) * | 2005-09-01 | 2012-10-23 | Plasma Technologies, Llc | Ultra-high yield of alpha-1-anti-trypsin |
| CN101316794B (zh) | 2005-10-06 | 2016-01-06 | 派克逖克斯公司 | 流体的电化学离子交换处理 |
| US7727399B2 (en) * | 2006-05-22 | 2010-06-01 | The Trustees Of Columbia University In The City Of New York | Systems and methods of microfluidic membraneless exchange using filtration of extraction outlet streams |
| CA2714594A1 (en) * | 2008-02-04 | 2009-08-13 | Edward F. Leonard | Fluid separation devices, systems and methods |
| TW201041899A (en) * | 2009-04-13 | 2010-12-01 | Bristol Myers Squibb Co | Protein purification by citrate precipitation |
| WO2010129724A2 (en) * | 2009-05-05 | 2010-11-11 | Anne Schwartz | Efficient biomass fractionating system for an energy pulse crop |
| EP3204062B1 (en) | 2014-10-07 | 2021-01-20 | Haemonetics Corporation | System and method for washing shed blood |
| WO2017223318A1 (en) | 2016-06-24 | 2017-12-28 | Dominique Uhlmann | System and Method for Continuous Flow Red Blood Cell Washing |
| US10815270B1 (en) * | 2019-09-20 | 2020-10-27 | Plasma Technologies, Llc | Compositions and methods for high efficiency protein precipitation |
| WO2021054999A1 (en) * | 2019-09-20 | 2021-03-25 | Plasma Technologies, Llc | Therapeutic protein compositions and methods |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1600161A (en) * | 1926-04-15 | 1926-09-14 | Government | Process of separating proteins and other matter from whey in soluble form |
| US1718282A (en) * | 1927-02-16 | 1929-06-25 | Firm Elektro Osmose Ag Graf Sc | Medical serum |
| US2461505A (en) * | 1944-12-02 | 1949-02-15 | Sun Chemical Corp | Removal or replacement of electrolytes in physiologically active materials |
| US2692854A (en) * | 1951-01-08 | 1954-10-26 | American Instr Co Inc | Mechanical dialyzer |
| US2726235A (en) * | 1953-03-02 | 1955-12-06 | Rane Leo | Method for the separation of proteins |
| US2790790A (en) * | 1954-11-10 | 1957-04-30 | Swift & Co | Protein fractionation |
| US3038838A (en) * | 1958-11-20 | 1962-06-12 | Merck & Co Inc | Method of producing purified properdin |
| US3234199A (en) * | 1958-12-18 | 1966-02-08 | Allen F Reid | Ion exchange process for separating proteins |
| US3203865A (en) * | 1962-11-30 | 1965-08-31 | Dow Chemical Co | Hog serum antibody concentrate |
| DK100842C (da) * | 1962-12-10 | 1965-01-25 | Novo Terapeutisk Labor As | Fremgangsmåde ved udvinding af plasminogen ud fra blodserum. |
| US3429867A (en) * | 1965-04-30 | 1969-02-25 | Microbiological Ass Inc | Serum substantially free from gamma globulin and method of preparing same |
| BE759625A (fr) * | 1969-12-10 | 1971-04-30 | Molkereigenossenschaft Dahlenb | Procede et dispositif pour la dialyse du lait, en particulier pour l'obtention de l'albumine du lait et du petit-lait |
| US3706631A (en) * | 1970-10-08 | 1972-12-19 | John D Falk | Sterilization of protein-containing fluids |
| FR2129165A5 (OSRAM) * | 1971-03-17 | 1972-10-27 | Rhone Poulenc Sa | |
| US3743480A (en) * | 1971-04-09 | 1973-07-03 | Allied Chem | Sterilization of biological fluids |
| DE2801123C2 (de) * | 1977-01-26 | 1986-01-02 | Armour Pharma GmbH & Co KG, 3440 Eschwege | Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates |
| NL7703937A (nl) * | 1977-04-12 | 1978-10-16 | Organon Teknika Bv | Inrichting voorzien van een sorbent voor het zuiveren van bloed; een voor orale toepassing geschikt sorbent en een werkwijze voor vervaar- diging van het sorbent. |
| US4136094A (en) * | 1977-08-31 | 1979-01-23 | The Regents Of The University Of Minnesota | Preparation of intravenous human and animal gamma globulins and isolation of albumin |
| US4264589A (en) * | 1978-12-20 | 1981-04-28 | Felts James M | Separation of active α1 -acid glycoprotein and utilization in the lipoprotein lipase enzyme system |
-
1980
- 1980-10-16 US US06/197,441 patent/US4321192A/en not_active Expired - Lifetime
-
1981
- 1981-02-26 CA CA000371840A patent/CA1142175A/en not_active Expired
- 1981-03-12 IT IT48007/81A patent/IT1142464B/it active
- 1981-03-19 FR FR8105535A patent/FR2492270A2/fr active Granted
- 1981-03-30 DE DE19813112539 patent/DE3112539A1/de not_active Withdrawn
- 1981-03-31 JP JP56046588A patent/JPS5772916A/ja active Pending
- 1981-04-08 GB GB8110976A patent/GB2085446B/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087695A (en) * | 1988-07-29 | 1992-02-11 | Mcy Laboratories Canada, Inc. | Immunoglobulin extraction utilizing properties of colloidal solutions |
Also Published As
| Publication number | Publication date |
|---|---|
| US4321192A (en) | 1982-03-23 |
| GB2085446A (en) | 1982-04-28 |
| FR2492270B2 (OSRAM) | 1984-03-16 |
| GB2085446B (en) | 1984-08-22 |
| IT8148007A0 (it) | 1981-03-12 |
| JPS5772916A (en) | 1982-05-07 |
| IT1142464B (it) | 1986-10-08 |
| FR2492270A2 (fr) | 1982-04-23 |
| DE3112539A1 (de) | 1982-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1142175A (en) | Fractionation of protein mixtures by salting out followed by dialysis treatment | |
| US4322275A (en) | Fractionation of protein mixtures | |
| US4351710A (en) | Fractionation of protein mixtures | |
| US4276140A (en) | Electrodialysis apparatus and process for fractionating protein mixtures | |
| JP4031833B2 (ja) | プリオンのクロマトグラフィー除去方法 | |
| Drukker | Haemodialysis: a historical review | |
| Chenoweth et al. | Anaphylatoxin formation during hemodialysis: Comparison of new and re-used dialyzers | |
| KR100273010B1 (ko) | 혈액-유래조성물로부터 응고인자를 보존시키며 항체를 제거하는 방법 | |
| DK166763B1 (da) | Immunoglobulin-g-holdig fraktion | |
| US4966709A (en) | Thermofiltration of plasma | |
| JPH08193031A (ja) | 水性液体からの腫瘍壊死因子αおよび細菌リポ多糖の同時除去方法 | |
| DE2404041A1 (de) | Blut-fraktionierungsverfahren | |
| US5080796A (en) | Thermofiltration of plasma | |
| CA1285480C (en) | Plasma exchange composition | |
| CA2052809A1 (en) | Process for producing secretory immunoglobulin a preparations | |
| CH626256A5 (en) | Device for the continuous, extracorporal separation of specific substances from blood | |
| Kaenhy et al. | Relationship between dialyzer reuse and the presence of anti-N-like antibodies in chronic hemodialysis patients | |
| US4322403A (en) | Method for the preparation of an immune globulin solution suitable for intravenous use | |
| JPS5910523A (ja) | 血液凝固因子８：ｃの製造方法 | |
| Parzer et al. | Plasma protein adsorption to hemodialysis membranes: studies in an in vitro model | |
| JP2002540912A (ja) | 生物学的混入物の除去 | |
| Scudder | STUDIES IN BLOOD PRESERVATION*: THE STABILITY OF PLASMA PROTEINS | |
| Deppisch et al. | Biocompatibility of the polyamide membranes | |
| Valbonesi et al. | Management of immune-mediated and paraproteinemic diseases by membrane plasma separation and cascade filtration | |
| JPS6164259A (ja) | 血漿蛋白質分画分離剤および装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |